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Pharmacovigilance is the science of adverse drug 
reactions (ADRs) and drug-related problems: 
their detection, assessment, management and 
prevention.[1] In 1992, South Africa (SA) was the 
first country in Africa to become a member of the 
World Health Organization (WHO) International Drug Monitoring 
Programme which co-ordinates international pharmacovigilance 
activities. Traditionally, pharmacovigilance activities were limited 
to spontaneous reporting of ADRs, which has been the mainstay 
of regulatory pharmacovigilance activities for many years. More 
recently, pharmacovigilance encompasses a growing range of 
quantitative and qualitative methods, which have become an integral 
part of the process for registration of medicines. Pharmacovigilance is 
recognised as an important component of monitoring and evaluation 
of public health programmes and medical institutions.[1] 
Pharmacovigilance is a responsibility shared with the medicine 
regulatory authority, public health programmes, the pharmaceutical 
industry, and the Essential Drugs Programme (EDP). As 
pharmacovigilance initiatives evolve and expand in SA, a national 
consolidated plan that integrates programmatic, regulatory and 
clinical/institutional pharmacovigilance is needed. This plan would 
strive to ensure that pharmacovigilance systems prioritise key 
national medicine safety concerns; are methodologically robust and 
ethical; and communicate their data and findings effectively to ensure 
that the data are used to inform policy and improve patient care. 
In August 2012, key stakeholders attended a national 
pharmacovigilance workshop hosted by the National Department of 
Health (NDoH) in collaboration with the University of Cape Town 
(UCT) supported by a grant from the US Centers for Disease Control 
and Prevention (CDC). The workshop aimed to obtain an overview 
of non-regulatory pharmacovigilance activities being conducted in 
the public sector, and to identify key strengths, shortcomings, and 
opportunities for strengthening and unifying these activities into a 
coherent national pharmacovigilance plan. 
Status of pharmacovigilance 
activities in SA
Before the workshop, we conducted a survey of non-regulatory 
pharmacovigilance programmes run by government, academic 
and other non-governmental institutions. We identified 
pharmacovigilance systems for the immunisation, HIV and 
tuberculosis (TB) programmes (four provincial systems and two 
co-ordinated by the NDoH) and for specific clinical specialties 
(paediatric HIV and dermatology). Surveillance methods included 
targeted spontaneous reporting (TSR) for specific drugs or patient 
groups, active surveillance for adverse reactions nested within 
existing cohort studies (two provincial systems) and cohort event 
monitoring (CEM) (two systems for patients receiving antiretroviral 
(ARV) medicines). 
While these pharmacovigilance programmes generate potentially 
useful information, there is little collaboration between programmes, 
even where the same approach, medicines and patient populations 
were targeted. Case definitions for solicited adverse events and 
pharmacovigilance terms differ so that data could not be meaningfully 
pooled. Case record forms, criteria for reporting and the purposes of 
reporting differ between similar TSR systems. The two CEM projects 
initiated for ARVs in two provinces were suspended owing to resource 
constraints. An active hospital surveillance system at one tertiary 
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hospital contributes data to a multicentre, international dermatology 
registry but there were no links between this system and provincial 
and national custodians of pharmacovigilance. Generally, outputs of 
existing systems are limited and were rarely used in policy decision-
making. The TSR programmes for HIV and TB medicines in four 
provinces provide some feedback to reporters by means of annual 
newsletters, periodic multidisciplinary case audits or telephonic 
feedback. Improved analysis and communication of the data was 
recognised as an important area for strengthening in all cases. The 
survey highlighted the need for greater collaboration between the 
pharmacovigilance programmes so that expertise, experience and 
resources can be shared and data pooled and compared. 
There was acknowledgement that other pharmaco-epidemiological 
approaches, e.g. nesting drug safety studies within existing sentinel 
cohorts and case control studies, have improved our understanding 
of medicines safety in SA. Local studies exploring safety of stavudine, 
which contributed to changes in policy, highlighted the value of such 
investigator-initiated research.[2-8] Cohort studies are an important 
source of pharmacovigilance data as they determine ADR incidence, 
which is needed to inform policy. 
National pharmacovigilance plan
The meeting agreed that a national pharmacovigilance plan should be 
underpinned by five key principles: 
• Regulatory, programmatic and institutional pharmacovigilance (see 
box below) should be incorporated into a cohesive national system. 
To ensure complementarity between different pharmacovigilance 
programmes, including those of the Medicines Regulatory Authority 
(MRA), lines of data and communication flow must be clearly 
defined. An organogram that defines the roles, responsibilities of 
the MRA and pharmaceutical industry, the EDP and public health 
programmes and their relationship to each other is needed. 
• The national pharmacovigilance system should contribute to 
treatment policy decision-making and improved patient care. The 
pharmacovigilance system should prioritise safety issues that 
significantly impact on the health of South Africans. The meeting 
identified priority pharmacovigilance issues facing the HIV, 
TB, maternal and child health and immunisation programmes 
(Table 1). Existing SA pharmacovigilance programmes should be 
reviewed in terms of their performance in meeting their objectives, 
the scientific validity of the approach adopted and whether outputs 
address priority safety concerns. There was agreement that in the 
short-to-medium term pharmacovigilance surveillance should 
comprise the following approaches: 
• spontaneous reporting for all medicines co-ordinated by the 
MRA
• TSR for public health programmes including HIV, TB and 
immunisation
• improved collection of medicines safety data within existing 
cohorts (e.g. HIV cohorts)
• a pregnancy exposure registry, which will be a sentinel 
surveillance system for medicines used in pregnancy. 
• The national pharmacovigilance system should incorporate 
both passive and active surveillance methods and should build 
on what already exists and has shown success. Both active and 
passive surveillance systems provide important medicines safety 
Table 1. Programmatic pharmacovigilance priorities in SA
HIV/AIDS 
•  Safety of tenofovir as a first-line ARV – especially 
nephrotoxicity and bone/skeletal toxicity risk
•  Safety of ARVs in pregnancy – particularly EFV
•  Safety of medicines used for common comorbidities in 
HIV-infected patients (i.e. drug-drug interactions, e.g. 
with anti-diabetic)
•  Serious skin reactions with TB and HIV medicines 
TB
• Safety of drugs for MDR- and XDR-TB:
• issues of formulations and quality 
• paediatric MDR and XDR dosing
• Drug-drug interactions with HIV drugs and treatments for 
comorbidities
• Deafness (ototoxicity) associated with use of aminoglycosides 
(‘mycins’)
• Hepatotoxicity associated with first- and second-line TB regimens 
Maternal and child health
• Risk of medicine-related harm to pregnant woman and fetus, 
e.g. PMTCT regimens, co-trimoxazole, fluconazole, TB 
medicines and novel vaccines
• EMB and ocular toxicity in children with TB
• Long-term effects of first-line protease inhibitors in children
• Safety of recommended ARV regimens in children
• Safety of NVP and TDF in children
• EFV and neurodevelopmental effects with in utero exposure
Immunisation and vaccines
• Efficacy and safety of vaccines in HIV/ 
immunocompromised patients
• BCG vaccinated neonates of HIV-infected mothers – 
safety and implementation of current guidelines
• Improved detection of serious events such as intestinal 
intussusceptions
Cross-cutting issues
• Poorly tolerated medicines and their impact on adherence
• Drug resistance – early warning indicators* 
• Safety of traditional medicines
ARV = antiretroviral; EFV = efavirenz; TB = tuberculosis; MDR = multi-drug resistant;  
XDR = extensively drug resistant; PMTCT = prevention of mother-to-child transmission; 
EMB = ethambutol; NVP = nevirapine; TDF = tenofovir.
*  Drug resistance and lack of efficacy of anti-infective drugs, while included as a 
pharmacovigilance issue, requires unique and specific expertise and surveillance. The 
National Health and Laboratory Service has already embarked on such work. This would 
need to be taken into account when a national pharmacovigilance system is developed 
further. 
• Regulatory pharmacovigilance focuses on developing a greater 
understanding of the risk-benefit profile of all registered 
medicines, the focus being on assessing the merit of the products 
on the market. 
• Public health pharmacovigilance programmes target their 
activities towards minimising the risk of preventable harms 
associated with recommended treatments or regimens and 
maintaining public trust. 
• Institutional/clinical pharmacovigilance aims to minimise 
medicines-related morbidity and mortality and the costs incurred 
in managing ADRs at clinical institutions (i.e. clinics and hospitals).
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information. Policy-makers and stakeholders need to appreciate 
the strengths and limitations of each approach. Passive surveillance 
systems for spontaneous reports of ADRs are useful in detecting 
signals of unknown or poorly understood ADRs and are important 
for improving patient care at institutional level. However, they 
cannot provide epidemiological information, such as incidence 
of ADRs, or compare the relative safety of two medicines, which 
is essential for changing public health policy. Active surveillance 
within sentinel cohorts can determine the incidence and risk 
factors for specific ADRs. The CEM system requires that a cohort 
of at least 20 000 patients per treatment regimen be monitored over 
time.[9] There was general agreement that this costly and labour-
intensive approach was not appropriate for the SA context. Instead, 
drug safety analyses should be nested within existing cohorts and 
cohort collaborations.
• Investment in capacity building and training in pharmacovigilance 
and pharmaco-epidemiology is critical to the success of the system. 
The NDoH, training institutions and partners need to support 
clinical staff by providing drug information support and training. 
Training of relevant stakeholders (e.g. EDP, pharmacy and 
therapeutic committees, disease programme managers) in the 
analysis, interpretation and communication of pharmacovigilance 
data is a priority. Academic institutions should be supported 
to develop postgraduate courses in pharmacovigilance and 
pharmaco-epidemiology. 
• Feedback and communication to stakeholders (from community to 
government) must be prioritised to ensure success and sustainability 
of the pharmacovigilance programme. The survey identified 
poor communication and feedback as major weaknesses of the 
existing pharmacovigilance systems. Platforms, such as a national 
pharmacovigilance website, that facilitate information sharing 
between researchers, policy-makers, pharmaceutical industry, 
clinicians, patients and the public should be created and supported. 
The NDoH requires a robust data management system that can 
respond to the requirements of the national pharmacovigilance 
plan. The data management system should allow for routine 
analysis and reporting of data, including feedback to reporters and 
other relevant stakeholders. 
Progress to date
The NDoH has already embarked on addressing the recommendations 
that arose from the workshop and has appointed a co-ordinator to 
facilitate implementation. 
A national decentralised TSR system for HIV and TB is being 
established and is at various phases of implementation in six provinces. 
Spontaneous reports are reviewed by a sub-district multidisciplinary 
health team to identify important reporting trends and preventable 
factors, including medication errors and system errors. It is hoped 
that this non-punitive multidisciplinary approach to reviewing ADR 
cases at institutional level will encourage spontaneous reporting, 
support clinical governance and improved management of patients 
with ADRs. 
The NDoH is implementing a national pregnancy exposure 
registry and birth defect surveillance programme at sentinel sites 
throughout the country to assess the safety of medicines commonly 
used in pregnancy. Instances of serious ADRs in pregnant woman 
and the incidence of adverse birth outcomes such as stillbirth, low 
birth weight, and congenital anomalies will be determined.[10] The 
first site is currently being initiated in KwaZulu-Natal province. 
Way forward
The relationship between the MRA, public health programmes 
and clinical services management within the NDoH needs to 
be clarified and operationalised. A key recommendation of the 
workshop was the creation of a national pharmacovigilance policy 
that will underpin the SA pharmacovigilance system. Such a policy 
would set the stage for an ethical and scientifically sound national 
pharmacovigilance programme that could significantly benefit 
public health and patient care. 
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